Probatebeta
Target

SLC6A3

Sodium-dependent dopamine transporter

As of the edition of 20 October 2026, SLC6A3 (sodium-dependent dopamine transporter, UniProt Q01959) has 30 drugs tested at it and 56 companies on the list, 8 on route A and 12 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q01959
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
17
Disease areas
Mental health; Nervous system; Chemically induced; Nutrition and metabolism; Cancer; Lungs and airways; Urinary and reproductive; Heart and blood vessels
Registered trials of its drugs
1,021

Drugs at this target

StatusCount
Marketed16
Active1
Went quiet5
Stopped4
Withdrawn from market4
Total30
DrugStatusFurthest phaseUS protection
MethylphenidateMarketedPhase 4none listed
BupropionMarketedPhase 4none listed
ModafinilMarketedPhase 4none listed
LisdexamfetamineMarketedPhase 4none listed
ArmodafinilMarketedPhase 4none listed
DextroamphetamineMarketedPhase 4none listed
AmphetamineMarketedPhase 4none listed
CentanafadineMarketedPhase 3none listed
SibutramineWithdrawn from marketPhase 4none listed
MethamphetamineMarketedPhase 4none listed
DexmethylphenidateMarketedPhase 4none listed
IoflupaneMarketedPhase 4none listed

12 of 30 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A8
Route B12
Engaged18
Undetermined18
Total on the list56
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
Bristol Myers SquibbRoute A
TakedaRoute B

The other 53 companies at SLC6A3

In the product

56 companies in all; 53 are not named here, and no score is.

See the 56 companies at SLC6A3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SLC6A3

Other targets in mental health

Companies holding approvals at SLC6A3